Global Blood Therapeutics (United States)

A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease

Elliott Vichinsky, Carolyn Hoppe, Kenneth I. Ataga et al. · New England Journal of Medicine · 2019 · 581 citations · Full text

Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease

Deborah P. Lubeck, Irene Agodoa, Nickhill Bhakta et al. · JAMA Network Open · 2019 · 308 citations · Full text

In silico toxicology protocols

Glenn J. Myatt, Ernst Ahlberg, Yumi Akahori et al. · Regulatory Toxicology and Pharmacology · 2018 · 234 citations · Full text

Toxicology Testing, Environmental Health, Toxicology +18

<scp>GBT</scp>440 increases haemoglobin oxygen affinity, reduces sickling and prolongs <scp>RBC</scp> half‐life in a murine model of sickle cell disease

Donna Oksenberg, Kobina Dufu, Mira Patel et al. · British Journal of Haematology · 2016 · 232 citations · Full text

Vitro Hbs Polymerization, Immunology, Selective Partitioning +19

Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

Thomas Powles, Kobe Yuen, Silke Gillessen et al. · Nature Medicine · 2022 · 231 citations · Full text

Urology, Medicine, Enzalutamide Versus +7